ArticleInternational journal of nanomedicine2020
Mechanism Investigation of Hyaluronidase-Combined Multistage Nanoparticles for Solid Tumor Penetration and Antitumor Effect.
Article in International journal of nanomedicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 46 citations in OpenAlex.
- Advances in Nanoarchitectural Designs for Anticancer Drug Delivery to Deep Tumors.Small (Weinheim an der Bergstrasse, Germany) · 2026Review
- Anomalous Diffusion of Nanoparticles in Semidilute Hyaluronic Acid Solutions.Biomacromolecules · 2026Article
- From permeation enhancer to therapeutic enabler: Advances, applications, and translational perspectives in hyaluronidase-based drug delivery.Materials today. Bio · 2026Review
- Nanotechnology in triple-negative breast cancer: a review of nanocarrier systems for enhanced efficacy and reduced toxicity.Nanoscale advances · 2026Review
- Review
- Hyaluronidase treatment is associated with increased cytokine levels and reduced peritoneal neutrophil accumulation during LPS-induced inflammation.Frontiers in pharmacology · 2026Article
- Deep Tumor Penetration Using Nanoparticle Delivery Systems: Programmed Design Strategies and Emerging Evaluation Platforms.International journal of nanomedicine · 2026Review
- Natural Polymers Based Biocompatible Nanomedicines for Targeting Colon Cancer: Prospects and Challenges.International journal of nanomedicine · 2026Review
- Bio-Polymers Based Functionalized Hydrogel Carriers for Targeted Oncology Therapies: Current Progress and Future Perspectives.International journal of nanomedicine · 2026Review
- Sequential-Delivery Gel Microspheres Integrating HAase-Mediated ECM Remodeling and GA-Active Targeting for Deep Tumor Penetration in TACE-Treated HCC.International journal of nanomedicine · 2026Article
- Advances in nanomaterials for enhancing cGAS-STING pathway mediated anti-tumor treatment.Materials today. Bio · 2025Review
- Formulation Strategies for Immunomodulatory Natural Products in 3D Tumor Spheroids and Organoids: Current Challenges and Emerging Solutions.Pharmaceutics · 2025Review
- Hyaluronidase: structure, mechanism of action, diseases and therapeutic targets.Molecular biomedicine · 2025Review
- Migrasomes as intercellular messengers: potential in the pathological mechanism, diagnosis and treatment of clinical diseases.Journal of nanobiotechnology · 2025Review
- Strategies for specific multimodal imaging of cancer-associated fibroblasts and applications in theranostics of cancer.Materials today. Bio · 2025Review
- The Extracellular Matrix Limits Nanoparticle Diffusion and Cellular Uptake in a Tissue-Specific Manner.bioRxiv : the preprint server for biology · 2024Article
- A Recombinant Oncolytic Pseudorabies Virus ExpressingMicroorganisms · 2023Article
- Hyaluronidase-trigger nanocarriers for targeted delivery of anti-liver cancer compound.RSC advances · 2023Article
- Tumor extracellular matrix modulating strategies for enhanced antitumor therapy of nanomedicines.Materials today. Bio · 2022Review
- Antioxidant, Enzyme, and HAntioxidants (Basel, Switzerland) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHyaluronic acid (HA) is a major component of extracellular matrix (ECM) and its over expression in tumor tissues contributes to the increase of interstitial fluid pressure (IFP) and hinders the penetration of nanoparticles into solid tumors. MATERIALS AND
methodsWe here reported a tumoral microenvironment responsive multistage drug delivery system (NPs-EPI/HAase) which was formed layer by layer via electrostatic interaction with epirubicin (EPI)-loaded PEG-b-poly(2-(diisopropylamino)ethyl methacrylate)-b-poly(2-guanidinoethylmethacrylate) (mPEG-PDPA-PG, PEDG) micelles (NPs-EPI) and hyaluronidase (HAase). In this paper, we focused on the hyaluronidase-combined nanoparticles (NPs-EPI/HAase) for tumor penetration in tumor spheroid and solid tumor models in vitro and in vivo.
resultsOur results showed that NPs-EPI/HAase effectively degrade the HA in ECM and facilitate deep penetration of NPs-EPI into solid tumor. Moreover, NPs-EPI mainly employed clathrin-mediated and macropinocytosis-mediated endocytic pathways for cellular uptake and were subsequently directed to the lysosomes for further drug release triggered by proton sponge effect. Compared with NPs-EPI, the HAase coating group showed an enhanced tumoral drug delivery efficacy and inhibition of tumor growth.
conclusionOverall, our studies demonstrated that coating nanoparticles with HAase can provide a simple but efficient strategy for nano-drug carriers to enhance solid tumor penetration and chemotherapeutic efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.